Liquidia Technologies, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2004-01-01
- Employees
- 101
- Market Cap
- $741M
- Website
- http://www.liquidia.com
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
- Conditions
- Interstitial Lung DiseasePulmonary Hypertension
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Liquidia Technologies, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06129240
- Locations
- 🇺🇸
The Medical Research Group, Inc., Fresno, California, United States
🇺🇸University of California San Diego, La Jolla, California, United States
🇺🇸National Jewish Health, Denver, Colorado, United States
A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
- Conditions
- Pulmonary Arterial HypertensionPulmonary Hypertension Due to Lung Diseases
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Liquidia Technologies, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT04691154
- Locations
- 🇺🇸
Arizona Pulmonary Specialists, Phoenix, Arizona, United States
🇺🇸VA Greater Los Angeles Healthcare, Los Angeles, California, United States
🇺🇸Mayo Clinic Jacksonville, Jacksonville, Florida, United States
Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil
- Conditions
- Primary Pulmonary Hypertension
- Interventions
- Drug: LIQ861 Inhaled Treprostinil
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Liquidia Technologies, Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT03992755
- Locations
- 🇺🇸
Banner University Medical Center, Phoenix, Arizona, United States
🇺🇸Arizona Pulmonary Specialists, Ltd., Phoenix, Arizona, United States
🇺🇸West Los Angeles VA Healthcare Center, Los Angeles, California, United States
Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Inhaled dry powder treprostinil (LIQ861)
- First Posted Date
- 2019-03-21
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- Liquidia Technologies, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03884465
- Locations
- 🇫🇷
CHRU de Nancy, Nancy, Vandoeuvre Les Nancy, France
🇫🇷CHU de Bicetre, Le Kremlin-Bicêtre, France
🇩🇪Studienambulanz fur Pulmonale Hypertonie at Medizinishe Klinik II, Universitatskinikum Giessen und Marburg GmbH, Gießen, Germany
Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil
- Conditions
- Primary Pulmonary Hypertension
- Interventions
- Drug: LIQ861 Inhaled Treprostinil
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Liquidia Technologies, Inc.
- Target Recruit Count
- 121
- Registration Number
- NCT03399604
- Locations
- 🇺🇸
Banner University Medical Center, Phoenix, Arizona, United States
🇺🇸Arizona Pulmonary Specialists, Ltd., Phoenix, Arizona, United States
🇺🇸West Los Angeles VA Healthcare Center, Los Angeles, California, United States
Single Ascending Dose Study of Two Liquidia Bupivacaine Formulations
- Conditions
- Acute Pain
- Interventions
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2017-08-24
- Lead Sponsor
- Liquidia Technologies, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT02982889
- Locations
- 🇩🇰
DanTrial Aps, Copenhagen, Denmark
A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001
- Conditions
- Influenza
- First Posted Date
- 2010-10-20
- Last Posted Date
- 2013-03-01
- Lead Sponsor
- Liquidia Technologies, Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT01224262
- Locations
- 🇺🇸
Accelovance - Melbourne, Melbourne, Florida, United States